Twist Bioscience Co. (NASDAQ:TWST) Receives $41.67 Average Price Target from Analysts

Twist Bioscience Co. (NASDAQ:TWST) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $42.50.

TWST has been the subject of several research reports. Barclays raised their target price on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Evercore ISI increased their price objective on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Robert W. Baird increased their price objective on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Finally, Scotiabank increased their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday.

Insider Activity

In other news, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the sale, the chief executive officer now directly owns 516,409 shares in the company, valued at $19,329,188.87. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Emily M. Leproust sold 4,163 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the completion of the sale, the chief executive officer now directly owns 509,986 shares in the company, valued at $18,935,780.18. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the sale, the chief executive officer now owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,415 shares of company stock worth $614,504. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. bought a new position in Twist Bioscience during the third quarter worth about $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in Twist Bioscience by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after buying an additional 721 shares during the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience during the fourth quarter worth about $30,000. Allspring Global Investments Holdings LLC boosted its holdings in Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after buying an additional 1,179 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in Twist Bioscience during the first quarter worth about $124,000.

Twist Bioscience Stock Up 4.3 %

Shares of TWST stock opened at $43.20 on Friday. Twist Bioscience has a 12 month low of $11.81 and a 12 month high of $44.92. The business’s 50 day moving average is $34.26 and its two-hundred day moving average is $31.67. The company has a market cap of $2.52 billion, a PE ratio of -12.86 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million during the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. Twist Bioscience’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share. As a group, equities analysts expect that Twist Bioscience will post -3.17 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.